MedEsthetics

NOVEMBER 15, 2024

We're diving into the "Ozempic Face" phenomenon to examine Ozempic's various effects on facial skin, what causes these side effects and separating the myths from the truth about its impact on facial aesthetics.

Facials 109

Facials Treatments 109

Beauty Launchpad

NOVEMBER 15, 2024

Hairdustry is excited to announce the fifth annual Presley Poe and Friends event, set for April 26-27, 2025, in Frederick, Maryland. This year’s theme, “Tech Behind the Chair,” will showcase the latest innovations driving the future of hairstyling.

Innovations 98

Innovations 98

MedEsthetics

NOVEMBER 15, 2024

Supercharged with next-generation botanical extracts and proven barrier-rejuvenating ingredients, this mask enhances skin radiance for a visibly brighter, healthier complexion after just one use.

Extractions 78

Extractions Ingredients Collagen 78

AAFE - American Academy of Facial Esthetics

NOVEMBER 15, 2024

By Brigid Landrum, RN When it comes to enhancing your smile, the world of cosmetic procedures offers a variety of options to achieve your desired look. Two popular treatments that often come into play are lip fillers and lip flips. Both can help enhance the appearance of your lips, but they serve different purposes and are suitable for different needs.

Hydration 60

Hydration Injections Moisturization Treatments 60

Beauty Launchpad

NOVEMBER 15, 2024

Hairdustry is excited to announce the fifth annual Presley Poe and Friends event, set for April 26-27, 2025, in Frederick, Maryland. This year’s theme, “Tech Behind the Chair,” will showcase the latest innovations driving the future of hairstyling.

Innovations 52

Innovations 52

Dermatology Times

NOVEMBER 15, 2024

Case studies demonstrate success with radiofrequency microneedling for hypertrophic scars in Fitzpatrick IV through VI.

Scarring 45

Scarring Microneedling 45

Dermatology Times

NOVEMBER 15, 2024

Catch up on coverage from the third day of the 2024 Society of Dermatology Physician Associates Fall Conference in Las Vegas, Nevada.

Dermatology 41

Dermatology 41

The Dermatology Digest

NOVEMBER 15, 2024

The first subject has been dosed in the Phase III trial of the InnoCare Pharma’s novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for the treatment of atopic dermatitis (AD) in China. ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including AD and vitiligo.

Dermatitis 36

Dermatitis Safety Marketing Dermatology 36

Dermatology Times

NOVEMBER 15, 2024

Catch up on coverage from the second day of the 2024 Society of Dermatology Physician Associates Fall Conference in Las Vegas, Nevada.

Dermatology 41

Dermatology 41

The Dermatology Digest

NOVEMBER 15, 2024

The U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for dupilumab (Dupixent, Sanofi & Regeneron) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.

Safety 28

Safety Therapy Clinic Dermatology 28

Dermatology Times

NOVEMBER 15, 2024

At the 2024 SDPA Fall Conference, Sara Wilchowski, DMSc, MPAS, PA-C, highlighted the challenges and rewards of transitioning to industry roles, the impact of “Insta-Tok” on patient care, and the evolving landscape of dermatology.

Clinic 41

Clinic Dermatology 41

Dermatology Times

NOVEMBER 15, 2024

SDPA President Amber Blair, PA-C, discusses new member opportunities and recognizes PA leaders.

41

41

Dermatology Times

NOVEMBER 15, 2024

A poster presented at the 2024 SDPA Fall Conference demonstrated that clascoterone cream remains stable when paired with commonly prescribed acne topicals, supporting its role in multimodal therapy.

Treatments 41

Treatments Therapy 41

Dermatology Times

NOVEMBER 15, 2024

Dermatology physician associates via DPAF conduct skin checks at the Sun Bus during Fall Conference.

Dermatology 41

Dermatology 41

Dermatology Times

NOVEMBER 15, 2024

The target action date for the FDA decision is April 18, 2025.

Treatments 41

Treatments 41

Dermatology Times

NOVEMBER 15, 2024

Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.

Management 36

Management Safety Clinic 36

Dermatology Times

NOVEMBER 15, 2024

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

Dermatitis 36

Dermatitis Treatments 36

Dermatology Times

NOVEMBER 15, 2024

Michael Rubio, PA-C, previews the transformative programming and career-focused initiatives at this year’s Society of Dermatology Physician Associates Fall Conference in Las Vegas.

Dermatology 31

Dermatology Education 31

Dermatology Times

NOVEMBER 15, 2024

Panelists discuss how topical PDE4 inhibitors compare to traditional treatments like corticosteroids in terms of efficacy, safety, and long-term disease control, while also examining the unique formulations of roflumilast and crisaborole and their implications for skin penetration and patient experience; they highlight practical considerations for application, the management of adverse effects such as stinging and burning, and the distinct advantages of PDE4 inhibitors in addressing specific gap

Dermatitis 36

Dermatitis Safety Management Treatments 36